A comprehensive analysis of CMTM4 expression across multiple cancers using bioinformatics indicated that CMTM4 is most significantly downregulated in brain cancers and ccRCC, which implies a tissue-specific function of CMTM4. This evidence concerns the gene CMTM4 and nonpapillary renal cell carcinoma.